Luis Bello: vida y época. Su producción periodística y literaria

Taking into account the cultural and literary wealth of the first third of the twentieth century in Spain, this doctoral dissertation aims to increase our knowledge of literary journalism during that period through a monographic study of one of its greatest champions, the journalist and writer Luis Bello Trompeta (1872-1935). Although Bello enjoyed noteworthy success and popularity in life, he has since fallen into an almost complete yet unjustifiable oblivion. Bello’s lifetime coincided with a brilliant period of Spanish culture, one that is almost unanimously considered not simply a Silver Age but a veritable golden age of journalism in Spain. Nevertheless, the period is often unjustly reduced to a short list of names and works of extremely well known and well studied writers. There is a tendency to forget that such writers emerged within a vast, influential context comprising numerous cultural products, writers, and works that need to be recovered. More specifically, the general inclination to privilege the book as a period’s sole bearer of literary or testimonial significance often deprives us of richly complementary journalistic sources such as the chronicle or the newspaper report. Indeed, together with the book, such articles can help us achieve a broader understanding of both literary history and the personality of individual writers or the course of historical events. The fact that authors like Luis Bello are practically unknown today is likely related to the time-sensitive, intrinsically ephemeral nature of journalism, the print medium in which Bello published most of his work. Yet in spite of its passing nature, the press witnessed remarkable developments in Spain at the time, undergoing a transformative process of consolidation...

El fenotipo "basal-her2" en el cáncer de mama: caracterización clínico-molecular e implicaciones terapéuticas

Clinically HER2+ (cHER2+) breast cancer (BC), as exclusively determined by immunohistochemistry of HER2 protein overexpression and/or fluorescence in situ hybridization of HER2 gene amplification, has been largely considered a single disease entity in terms of clinical outcome and in the susceptibility to the anti-HER2 monoclonal antibody trastuzumab (Herceptin). However, although the adjuvant/neoadjuvant use of the trastuzumab has been shown to significantly reduce recurrence risk when added to standard chemotherapy in women with early-stage cHER2+ BC, not all cases derive similar benefit from trastuzumab because a significant number of cHER2+ BC patients develop disease recurrence. Unfortunately, the identification of a robust clinical predictor of trastuzumab benefit, including HER2 itself, has proven challenging in the adjuvant/neoadjuvant setting. Thus, we suggest that a new generation of research needs to refine the prognostic taxonomy of cHER2+ BC and develop easy-to-use, clinicbased prediction algorithms to distinguish between good- and poor- responders to trastuzumab-based therapy ab initio. This study offered two hypotheses: 1.) HER2 overexpression can unexpectedly take place in a molecular background owned by basal-like BC (a commonly HER2-negative BC subtype which possesses many epithelial-mesenchymal transition (EMT) characteristics and exhibits robust cancer stem cell [CSC]-like features), thus generating a so-called basal/cHER2+ BC subtype; 2.) the basal/cHER2+ phenotype confers poor prognosis and delineates a subgroup of intrinsically aggressive cHER2+ BC with primary resistance to trastuzumab...